FDA ap­proves Im­mu­ni­ty­Bio's blad­der can­cer ther­a­py com­bo

Im­mu­ni­ty­Bio scored an FDA ap­proval for its once-re­ject­ed drug com­bo for blad­der can­cer, the biotech an­nounced Mon­day, send­ing its stock up near­ly 25% in pre­mar­ket trad­ing.

The agency ap­proved the drug Ank­ti­va, an IL-15 ag­o­nist, in com­bi­na­tion with Bacil­lus Cal­mette-Guérin to treat pa­tients with a sub­type of BCG-un­re­spon­sive non-mus­cle in­va­sive blad­der can­cer (NMIBC). Im­mu­ni­ty­Bio’s stock $IBRX was trad­ing over $6 be­fore the mar­ket opened.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER